Dogwood Therapeutics Inc. Ordinary Shares DWTX 深 滬
等待開盤 11-03 09:30:00 美东时间
6.21
-0.440
-6.62%
華盛通- 最 高6.76
- 今 開6.69
- 成交量 12.30万股
- 最 低 6.14
- 昨 收 6.65
- 總市值 1186.79万
- 52周最高 29.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.62
- 委 比 42.86%
- 總股本 191.11万
- 歷史最高 417.75
- 量 比 1.06
- 振 幅 9.32%
- 歷史最低 1.87
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dogwood Therapeutics Announces Business Combination Plans
Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On October 9, 20...
10-10 04:55
Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the
10-07 20:49
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Electric aircraft maker Beta Technologies files for U.S. IPO
Beta Technologies, a U.S. electric-aircraft developer backed by Amazon, has submitted paperwork to go public via a U.S. IPO, seeking to capitalize on the strong equity market environment. The company,...
09-29 22:08
Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma
Dogwood Therapeutics ( ($DWTX) ) has shared an announcement. On September 29, 2...
09-29 19:58
Market-Moving News for September 29th
LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdrawn from its long-term study evaluating daily subcutaneous injections of
09-29 19:20
Dogwood shares are trading higher after the company secured a worldwide, royalty-free license to develop Serpin Pharma's SP16 IV formulation for cancer-related pain.
Dogwood shares are trading higher after the company secured a worldwide, royalt...
09-29 19:17
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
Dogwood Therapeutics acquires global license for Serpin Pharma's SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced neuropathy (CIPN) and cancer-related pain. SP16, with anti-inflammatory and neural repair properties, is set to begin Phase 1b trials in early 2026, fully funded by the National Cancer Institute. It complements Halneuron® (a late-stage NaV1.7 inhibitor) for synergistic pain relief. The transaction expands Dogwood's p...
09-29 11:15
长江生命科技(00775.HK)与DWTX订立弃权协议
长江生命科技(00775.HK)发布公告，诚如首份公告所披露，根据售股协议，向卖方(本公司全资附属公司)发行买方普通股付款股份及买方Dogwood Therapeutics, Inc(纳斯达克：DWTX)优先股付款股份乃作为向买方出售目标公司(Pharmagesic (Holdings) Inc)100%股权的代价，及买方优先股付款股份为卖方提供现金结算权及回购权。
09-26 22:30
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Dogwood Therapeutics (Nasdaq: DWTX) will participate in the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025, at the Lotte New York Palace Hotel. CEO Greg Duncan will join Sean Lee for a fireside chat on September 5, 2025, available on-demand at 7:00am ET. The presentation and replay can be accessed via the investor relations section of Dogwood's website. Duncan will be available for one-on-one meetings during the co...
09-03 13:15
